Novartis Reaches New 52-Week High (NVS)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- Novartis (NYSE: NVS) hit a new 52-week high Monday as it is currently trading at $61.97, above its previous 52-week high of $61.89 with 391,986 shares traded as of 10:10 a.m. ET. Average volume has been 2.2 million shares over the past 30 days.

Novartis has a market cap of $148.73 billion and is part of the health care sector and drugs industry. Shares are up 7.1% year to date as of the close of trading on Friday.

Novartis AG, through its subsidiaries, engages in the research, development, manufacture, and marketing of healthcare products worldwide. The company has a P/E ratio of 16.3, below the average drugs industry P/E ratio of 17.3 and below the S&P 500 P/E ratio of 17.7.

  • ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.

TheStreet Ratings rates Novartis as a buy. The company's strengths can be seen in multiple areas, such as its attractive valuation levels, largely solid financial position with reasonable debt levels by most measures, increase in stock price during the past year, increase in net income and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. You can view the full Novartis Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge! Free download now.
null